Find Patient Assistance
Answer a few simple questions to find out which patient assistance option might be right for your patient.
-
Is your patient insured?
-
Does your patient have commercial insurance?
What does this mean? -
Has your patient already been referred to the Rituxan Immunology Co-pay Card Program and is either ineligible or no longer receiving assistance?
-
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?
-
Is the patient using Rituxan for an FDA-approved indication?
Your Patient Might Qualify for a Referral to the Rituxan Immunology Co-pay Card Program
If eligible commercially insured patients need assistance with their out-of-pocket costs, Genentech Access Solutions can refer them to the Rituxan Immunology Co-pay Card Program.*
*In order to be eligible for the Rituxan Immunology Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They must also agree to the rules set forth in the terms and conditions for the program. Please visit RACopay.com for the full list of terms and conditions.
Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
For eligible patients with commercial or public health insurance, Genentech Access Solutions offers referrals to independent co-pay assistance foundations.*
*Genentech and Biogen do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s or Biogen's endorsement or financial support. There may be other foundations to support the patient's disease state.
Your Patient Might Qualify for a Referral to the Genentech® Access to Care Foundation (GATCF)
GATCF helps eligible patients who meet specific criteria receive Rituxan free of charge.*
*To be eligible for free Rituxan from GATCF, insured patients must have exhausted all other forms of patient assistance (including the Rituxan Immunology Co-pay Card Program and support from independent co-pay assistance foundations) and meet financial criteria. Uninsured patients must meet different financial criteria.
Patient Assistance Options
Referrals to the Rituxan Immunology Co-pay Card Program
Genentech Access Solutions can refer eligible patients to the Rituxan Immunology Co-pay Card Program for help with the out-of-pocket costs associated with Rituxan.*
Referrals to Independent Co-pay Assistance Foundations
For eligible patients with commercial or public health insurance, Genentech Access Solutions offers referrals to independent co-pay assistance foundations.†
Referrals to the Genentech® Access to Care Foundation (GATCF)
GATCF helps eligible patients who meet specific criteria receive Rituxan free of charge.‡
*In order to be eligible for the Rituxan Immunology Co-pay Card
Program, the patient must have commercial insurance, must not have
Medicare, Medicaid or other government insurance, and must meet other
eligibility criteria. They also must agree to the rules set forth in
the terms and conditions for the program. Please visit RACopay.com for
the full list of terms and conditions.
†Genentech and Biogen do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s or Biogen's endorsement or financial support. There may be other foundations to support the patient's disease state.
‡To be eligible for free medicine from GATCF, insured patients must
have exhausted all other forms of patient assistance (including the
Rituxan Immunology Co-pay Card Program and support from independent
co-pay assistance foundations) and meet financial criteria. Uninsured
patients must meet different financial criteria.
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
Indications
- Rituxan® (rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF antagonist therapies
- Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
- Rituxan® (rituximab) is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (PV)
BOXED WARNINGS and Additional Important Safety Information
Infusion Reactions: Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions
Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan
Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation
Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan
Warnings and Precautions
Rituxan administration can also result in additional serious, including fatal, adverse reactions including:
- Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function
- Infections: Withhold Rituxan and institute appropriate anti-infective therapy. Rituxan is not recommended for use in patients with severe, active infections
- Cardiovascular adverse reactions: Discontinue infusions in case of serious or life-threatening events
- Renal toxicity: Discontinue in patients with rising serum creatinine or oliguria
- Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms
- Immunizations: Live virus vaccinations prior to or during Rituxan treatment are not recommended
- Embryo-Fetal toxicity: Can cause neonatal harm. Advise of potential risk to neonates and use of effective contraception
- Concomitant Use with Other Biologic Agents and DMARDS other than Methotrexate in RA, GPA and MPA, PV: Patients with RA should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly. Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA or PV patients exhibiting peripheral B-cell depletion following treatment with Rituxan
- Use in RA Patients Who Have Not Had Prior Inadequate Response to Tumor Necrosis Factor (TNF) Antagonists: The use of Rituxan in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended
- Retreatment in Patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA): The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA
Most Common Adverse Reactions
Rheumatoid Arthritis (RA):
Most common adverse reactions (≥10%) in clinical trials: upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis. Other important adverse reactions include infusion reactions, serious infections, and cardiovascular events.
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA):
Most common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions.
Pemphigus Vulgaris (PV):
Most common adverse reactions (≥15%) in the clinical trial were infusion reactions, depression (other important adverse reactions include infections).
Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.
For additional Important Safety Information, please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide at www.rituxan.com.